Oncotarget Volume 11, Issue 4: The research team's aim was to investigate mAb 6G5j binding characteristics and to validate fluorescence targeting of colorectal tumors and metastases in patient derived orthotopic xenograft models with fluorescently labeled 6G5j.
Anti-CEACAM antibody 6G5j binds multiple CEACAMs which may lead to improved detection of tumor margins for tumors and metastases that have variable expression of CEA and other CEACAMs.
6G5j mAb may be useful for colon cancer detection for pre-surgical diagnosis and fluorescence-guided surgery.
Dr. Michael Bouvet from the Department of Surgery and the Moores Cancer Center at the University of California in La Jolla California USA as well as the VA San Diego Healthcare System in San Diego, CA, USA said in their Oncotarget article, "Early diagnosis and surgical resection of a wide variety of epithelial malignancies remain a vital challenge due to difficulty of intraoperative recognition of tumor margins and small metastases during minimally invasive procedures."
While immune cells and endothelium solely express CEACAM1, human epithelial cells show a much more complex CEACAM expression pattern.
While anti-CEA antibodies conjugated to fluorophores have enabled tumor visualization, the simultaneous targeting of multiple antigens may further enhance visualization, provide more distinct tumor margins and improve detection of metastases.
In this Oncotarget study, the authors test a novel anti-CEACAM antibody conjugated to a fluorescent dye for detection of multiple CEACAM antigens to enhance visualization of colorectal PDOX tumors and metastases in murine models.
The Bouvet Research Team concluded that since this mAb binds to multiple antigens that are commonly present in colon tumors, namely CEACAM1, 5 and 6, it may provide improved detection of cancer margins for tumors with variable expression of CEA and other CEACAMs. Further studies are necessary to validate the use of 6G5j-IR800CW in human patients with colorectal cancer.
Full text - https://doi.org/10.18632/oncotarget.27446
Correspondence to - Michael Bouvet - firstname.lastname@example.org
Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.